Li Liu, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 1 de noviembre del 2001
|Author: Vincent Anku, MD
Publisher: Achilles Publishers, Inc.
Hope -- At Last -- in Cancer Treatment is an excellent reference for cancer patients and their family members. The book is a comprehensive guide that empowers cancer patients to take an active role in their treatment. It is also of value to their caregivers. It provides examples of how to bring the complex oncologic concepts into the world that patients live in every day.
The author, Dr. Vincent Anku, received his M.D. from the Cornell Medical School and London University School of Tropical Medicine and Hygiene. He completed his internship and residency in medicine at Case Western Reserve in Cleveland, Ohio where he served as Assistant Professor of Medicine before entering private practice. Dr. Anku is Board Certified in four specialties: internal medicine, hematology, oncology, and tropical medicine. Presently, Dr. Anku is the Director of the Cleveland Cancer Institute.
The book is divided into four major sections. Section one is a brief introduction of the concept of oncology and some social issues associated with the diagnosis of cancer. Section two describes the various modalities used in cancer treatment. As a hematologist/oncologist, Dr. Anku discusses systemic chemotherapy in detail with up-to-date information, including the progress made in immunotherapy, gene therapy, and anti-sense therapy. Section three contains chapters that deal with some of the most common malignancies. The radiographic images are very well explained and extremely informative in helping patients to understand the diagnosis, staging, and treatment of cancers. Section four deals with issues of coping with cancer.
The entire book is extremely well organized and quite readable. OncoLink highly recommends this book.Imprima English
Mar 5, 2013 - For men with prostate cancer, treatment with irradiation is associated with lasting prostate cancer control, defined as a prostate-specific antigen cut-off of less than 0.2 ng/ml, with no recurrence seen from 15.5 to 25 years, according to a study published in the March issue of The Journal of Urology.
Apr 27, 2011
Nov 15, 2012
May 20, 2010